AU Patent

AU2014332191B2 — Dry powder inhaler

Assigned to Teva Branded Pharmaceutical Products R&D Inc · Expires 2020-04-02 · 6y expired

What this patent protects

This invention provides a dry powder inhaler comprising: a dry powder medicament comprising fluticasone propionate, salmeterol xinafoate and a lactose carrier; wherein, the delivered dose of salmeterol per actuation is less than 50 μg; and wherein the dose provides a baseline-adj…

USPTO Abstract

This invention provides a dry powder inhaler comprising: a dry powder medicament comprising fluticasone propionate, salmeterol xinafoate and a lactose carrier; wherein, the delivered dose of salmeterol per actuation is less than 50 μg; and wherein the dose provides a baseline-adjusted FEV

Drugs covered by this patent

Patent Metadata

Patent number
AU2014332191B2
Jurisdiction
AU
Classification
—
Expires
2020-04-02
Drug substance claim
No
Drug product claim
No
Assignee
Teva Branded Pharmaceutical Products R&D Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.